Cargando…
The timing of 30‐month stay expirations and generic entry: A cohort study of first generics, 2013–2020
ABSTRACT: Before the first generic version of a drug is marketed, patent litigation often occurs. The process begins when generic manufacturers notify the US Food and Drug Administration (FDA) of their intent to market a generic copy of a brand‐name drug protected by patents, which they allege to be...
Autores principales: | Kannappan, Sunand, Darrow, Jonathan J., Kesselheim, Aaron S., Beall, Reed F. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8504843/ https://www.ncbi.nlm.nih.gov/pubmed/33982425 http://dx.doi.org/10.1111/cts.13046 |
Ejemplares similares
-
The Case for Reforming Drug Naming: Should Brand Name Trademark Protections Expire upon Generic Entry?
por: Sarpatwari, Ameet, et al.
Publicado: (2016) -
Time to Marketing of Generic Drugs After Patent Expiration in Canada
por: Lexchin, Joel
Publicado: (2021) -
Regulatory Solutions to the Problem of High Generic Drug Costs
por: Luo, Jing, et al.
Publicado: (2015) -
Upstream solutions for price-gouging on critical generic medicines
por: Houston, Adam R., et al.
Publicado: (2016) -
Paying Physicians to Prescribe Generic Drugs and Follow-On Biologics in the United States
por: Sarpatwari, Ameet, et al.
Publicado: (2015)